[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Table 1.  
Baseline Characteristicsa
Baseline Characteristicsa
Table 2.  
Baseline Characteristics of Cerebral Venous Thrombosis Cases
Baseline Characteristics of Cerebral Venous Thrombosis Cases
Table 3.  
Association Between Obesity and Cerebral Venous Thrombosis
Association Between Obesity and Cerebral Venous Thrombosis
Table 4.  
Stratification by Sex
Stratification by Sex
Table 5.  
Stratification by Oral Contraceptive Use in Women
Stratification by Oral Contraceptive Use in Women
1.
Brækkan  SK, Hald  EM, Mathiesen  EB,  et al.  Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study.  Arterioscler Thromb Vasc Biol. 2012;32(2):487-491.PubMedArticle
2.
Tsai  AW, Cushman  M, Rosamond  WD, Heckbert  SR, Polak  JF, Folsom  AR.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.  Arch Intern Med. 2002;162(10):1182-1189.PubMedArticle
3.
Holst  AG, Jensen  G, Prescott  E.  Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study.  Circulation. 2010;121(17):1896-1903.PubMedArticle
4.
Pomp  ER, le Cessie  S, Rosendaal  FR, Doggen  CJ.  Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.  Br J Haematol. 2007;139(2):289-296.PubMedArticle
5.
Severinsen  MT, Kristensen  SR, Johnsen  SP, Dethlefsen  C, Tjønneland  A, Overvad  K.  Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.  Circulation. 2009;120(19):1850-1857.PubMedArticle
6.
Parkin  L, Sweetland  S, Balkwill  A, Green  J, Reeves  G, Beral  V; Million Women Study Collaborators.  Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study.  Circulation. 2012;125(15):1897-1904.PubMedArticle
7.
Zuurbier  SM, van den Berg  R, Troost  D, Majoie  CB, Stam  J, Coutinho  JM.  Hydrocephalus in cerebral venous thrombosis.  J Neurol. 2015;262(4):931-937.PubMedArticle
8.
Stam  J.  Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;352(17):1791-1798.PubMedArticle
9.
de Bruijn  SF, Stam  J, Koopman  MM, Vandenbroucke  JP; The Cerebral Venous Sinus Thrombosis Study Group.  Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions.  BMJ. 1998;316(7131):589-592.PubMedArticle
10.
Koopman  K, Uyttenboogaart  M, Vroomen  PC, van der Meer  J, De Keyser  J, Luijckx  GJ.  Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years.  Thromb Haemost. 2009;102(4):620-622.PubMed
11.
Zuurbier  SM, Lauw  MN, Coutinho  JM,  et al.  Clinical course of cerebral venous thrombosis in adult acute lymphoblastic leukemia.  J Stroke Cerebrovasc Dis. 2015;24(7):1679-1684.PubMedArticle
12.
Pearson  V, Ruzas  C, Krebs  NF, Goldenberg  NA, Manco-Johnson  MJ, Bernard  TJ.  Overweight and obesity are increased in childhood-onset cerebrovascular disease.  J Child Neurol. 2013;28(4):517-519.PubMedArticle
13.
deVeber  G, Andrew  M, Adams  C,  et al; Canadian Pediatric Ischemic Stroke Study Group.  Cerebral sinovenous thrombosis in children.  N Engl J Med. 2001;345(6):417-423.PubMedArticle
14.
Saposnik  G, Barinagarrementeria  F, Brown  RD  Jr,  et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention.  Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.  Stroke. 2011;42(4):1158-1192.PubMedArticle
15.
Blom  JW, Doggen  CJ, Osanto  S, Rosendaal  FR.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;293(6):715-722.PubMedArticle
16.
Donders  AR, van der Heijden  GJ, Stijnen  T, Moons  KG.  Review: a gentle introduction to imputation of missing values.  J Clin Epidemiol. 2006;59(10):1087-1091.PubMedArticle
17.
Abdollahi  M, Cushman  M, Rosendaal  FR.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;89(3):493-498.PubMed
18.
Kemmeren  JM, Tanis  BC, van den Bosch  MA,  et al.  Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.  Stroke. 2002;33(5):1202-1208.PubMedArticle
19.
Goldhaber  SZ, Grodstein  F, Stampfer  MJ,  et al.  A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;277(8):642-645.PubMedArticle
20.
Bonita  R, Beaglehole  R, Kjellstrom  T.  Environmental and Occupational Epidemiology: Basic Epidemiology. 2nd ed. Geneva, Switzerland: World Health Organization; 2006:93-95.
21.
De Pergola  G, De Mitrio  V, Giorgino  F,  et al.  Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution.  Int J Obes Relat Metab Disord. 1997;21(7):527-535.PubMedArticle
22.
Christiansen  SC, Lijfering  WM, Naess  IA,  et al.  The relationship between body mass index, activated protein C resistance and risk of venous thrombosis.  J Thromb Haemost. 2012;10(9):1761-1767.PubMedArticle
23.
Rosing  J, Middeldorp  S, Curvers  J,  et al.  Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.  Lancet. 1999;354(9195):2036-2040.PubMedArticle
24.
Schokker  DF, Visscher  TL, Nooyens  AC, van Baak  MA, Seidell  JC.  Prevalence of overweight and obesity in the Netherlands.  Obes Rev. 2007;8(2):101-108.PubMedArticle
25.
Wall  M, Kupersmith  MJ, Kieburtz  KD,  et al; NORDIC Idiopathic Intracranial Hypertension Study Group.  The Idiopathic Intracranial Hypertension Treatment Trial: clinical profile at baseline.  JAMA Neurol. 2014;71(6):693-701.PubMedArticle
26.
Biousse  V, Ameri  A, Bousser  MG.  Isolated intracranial hypertension as the only sign of cerebral venous thrombosis.  Neurology. 1999;53(7):1537-1542.PubMedArticle
27.
Leker  RR, Steiner  I.  Features of dural sinus thrombosis simulating pseudotumor cerebri.  Eur J Neurol. 1999;6(5):601-604.PubMedArticle
28.
Kesler  A, Goldhammer  Y, Gadoth  N.  Do men with pseudomotor cerebri share the same characteristics as women? a retrospective review of 141 cases.  J Neuroophthalmol. 2001;21(1):15-17.PubMedArticle
29.
Ferro  JM, Canhão  P, Stam  J, Bousser  MG, Barinagarrementeria  F; ISCVT Investigators.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).  Stroke. 2004;35(3):664-670.PubMedArticle
30.
Balcer  LJ, Liu  GT, Forman  S,  et al.  Idiopathic intracranial hypertension: relation of age and obesity in children.  Neurology. 1999;52(4):870-872.PubMedArticle
31.
Nedelmann  M, Kaps  M, Mueller-Forell  W.  Venous obstruction and jugular valve insufficiency in idiopathic intracranial hypertension.  J Neurol. 2009;256(6):964-969.PubMedArticle
32.
Wakerley  BR, Tan  MH, Ting  EY.  Idiopathic intracranial hypertension.  Cephalalgia. 2015;35(3):248-261.PubMedArticle
33.
Sugerman  HJ, DeMaria  EJ, Felton  WL  III, Nakatsuka  M, Sismanis  A.  Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri.  Neurology. 1997;49(2):507-511.PubMedArticle
34.
Rohr  A, Dörner  L, Stingele  R, Buhl  R, Alfke  K, Jansen  O.  Reversibility of venous sinus obstruction in idiopathic intracranial hypertension.  AJNR Am J Neuroradiol. 2007;28(4):656-659.PubMed
35.
Puffer  RC, Mustafa  W, Lanzino  G.  Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature.  J Neurointerv Surg. 2013;5(5):483-486.PubMedArticle
36.
Piper  RJ, Kalyvas  AV, Young  AM, Hughes  MA, Jamjoom  AA, Fouyas  IP.  Interventions for idiopathic intracranial hypertension.  Cochrane Database Syst Rev. 2015;8:CD003434.PubMed
37.
ClinicalTrials.gov. Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy (VSSIIH). NCT01407809. https://clinicaltrials.gov/ct2/show/NCT01407809. Accessed December 1, 2015.
38.
ClinicalTrials.gov. Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension. NCT02143258. https://clinicaltrials.gov/ct2/show/NCT02143258. Accessed December 1, 2015.
39.
Martinelli  I, Sacchi  E, Landi  G, Taioli  E, Duca  F, Mannucci  PM.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.  N Engl J Med. 1998;338(25):1793-1797.PubMedArticle
40.
Moons  KG, Donders  RA, Stijnen  T, Harrell  FE  Jr.  Using the outcome for imputation of missing predictor values was preferred.  J Clin Epidemiol. 2006;59(10):1092-1101.PubMedArticle
41.
Chou  KT, Huang  CC, Chen  YM,  et al.  Sleep apnea and risk of deep vein thrombosis: a non-randomized, pair-matched cohort study.  Am J Med. 2012;125(4):374-380.PubMedArticle
42.
Jordan  AS, McSharry  DG, Malhotra  A.  Adult obstructive sleep apnoea.  Lancet. 2014;383(9918):736-747.PubMedArticle
43.
Middeldorp  S.  Thrombosis in women: what are the knowledge gaps in 2013?  J Thromb Haemost. 2013;11(suppl 1):180-191.PubMedArticle
44.
van Vlijmen  EF, Veeger  NJ, Middeldorp  S,  et al.  Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.  Blood. 2011;118(8):2055-2061.PubMedArticle
Original Investigation
May 2016

Risk of Cerebral Venous Thrombosis in Obese Women

Author Affiliations
  • 1Department of Neurology, Academic Medical Centre, Amsterdam, the Netherlands
  • 2Department of Neurology, Inselspital Hospital University, Bern, Switzerland
  • 3Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands
  • 4Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the Netherlands
  • 5Division of Neuroradiology, Department of Medical Imaging, University Health Network and the University of Toronto, Toronto, Ontario, Canada
JAMA Neurol. 2016;73(5):579-584. doi:10.1001/jamaneurol.2016.0001
Abstract

Importance  Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism. To date, however, whether obesity is associated with adult cerebral venous thrombosis (CVT) has not been assessed.

Objective  To assess whether obesity is a risk factor for CVT.

Design, Setting, and Participants  A case-control study was performed in consecutive adult patients with CVT admitted from July 1, 2006 (Amsterdam), and October 1, 2009 (Berne), through December 31, 2014, to the Academic Medical Center in Amsterdam, the Netherlands, or Inselspital University Hospital in Berne, Switzerland. The control group was composed of individuals from the control population of the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study, which was a large Dutch case-control study performed from March 1, 1999, to September 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assessed. Data analysis was performed from January 2 to July 12, 2015.

Main Outcomes and Measures  Obesity was determined by body mass index (BMI). A BMI of 30 or greater was considered to indicate obesity, and a BMI of 25 to 29.99 was considered to indicate overweight. A multiple imputation procedure was used for missing data. We adjusted for sex, age, history of cancer, ethnicity, smoking status, and oral contraceptive use. Individuals with normal weight (BMI <25) were the reference category.

Results  The study included 186 cases and 6134 controls. Cases were younger (median age, 40 vs 48 years), more often female (133 [71.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women), and more frequently had a history of cancer (17 [9.1%] vs 235 [3.8%]) compared with controls. Obesity (BMI ≥30) was associated with an increased risk of CVT (adjusted odds ratio [OR], 2.63; 95% CI, 1.53-4.54). Stratification by sex revealed a strong association between CVT and obesity in women (adjusted OR, 3.50; 95% CI, 2.00-6.14) but not in men (adjusted OR, 1.16; 95% CI, 0.25-5.30). Further stratification revealed that, in women who used oral contraceptives, overweight and obesity were associated with an increased risk of CVT in a dose-dependent manner (BMI 25.0-29.9: adjusted OR, 11.87; 95% CI, 5.94-23.74; BMI ≥30: adjusted OR, 29.26; 95% CI, 13.47-63.60). No association was found in women who did not use oral contraceptives.

Conclusions and Relevance  Obesity is a strong risk factor for CVT in women who use oral contraceptives.

Introduction

Various studies16 have identified obesity as a risk factor for deep vein thrombosis of the leg and pulmonary embolism, collectively called venous thromboembolism (VTE). A body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) of 30 or more increases the risk of VTE approximately 2-fold compared with a normal BMI (<25), and this risk increases more with higher BMIs. Individuals with a BMI greater than 40 have an approximately 3 times higher risk.

Cerebral venous thrombosis (CVT) is a rare thrombotic condition that mainly affects young adults and children.7 Risk factors for CVT partly overlap with those for VTE and include thrombophilia, cancer, and oral contraceptive use.8,9 Other risk factors, such as local infections and head trauma, are specific for CVT.10 Some diseases, such as acute lymphoblastic leukemia, are associated with CVT and VTE, but the association is stronger for CVT.11

To our knowledge, whether obesity is associated with adult CVT has not been assessed. One study12 found that obesity is more common in children with CVT (55%) compared with controls (32%), but the sample size was small (22 cases). In addition, this study12 used historical controls and did not adjust for confounding variables. Moreover, because the clinical presentation and risk factors of CVT are different for children and adults,13 this result cannot be generalized to adult patients. In the current study, we examined whether obesity is a risk factor for adult CVT.

Box Section Ref ID

Key Points

  • Question: Is obesity a risk factor for cerebral venous thrombosis?

  • Findings: In this case-control study that included 186 cases and 6134 controls, obesity was associated with a statistically significant 3-fold increased risk of cerebral venous thrombosis. Stratification by sex revealed that in women who used oral contraceptives, the risk was increased 30-fold. In contrast, we found no association in men or women who did not use oral contraceptives.

  • Meaning: Obesity is a strong risk factor for cerebral venous thrombosis in women who use oral contraceptives.

Methods
Study Design and Patient Selection

We performed an unmatched case-control study. The controls were recruited from March 1, 1999, through September 31, 2004, and the cases were recruited from July 1, 2006 (Amsterdam), and October 1, 2009 (Berne), through December 31, 2014. Data analysis was performed from January 2 to July 12, 2015.

Cases were patients with CVT included in 2 prospective cohorts from the Academic Medical Center in Amsterdam, the Netherlands, and Inselspital University Hospital in Berne, Switzerland. In these hospitals, data on consecutive adult patients with CVT have been recorded since July 2006 (Amsterdam) and October 2009 (Berne). We included patients who were admitted until December 2014. The diagnosis of CVT was confirmed with computed tomography venography, magnetic resonance imaging and magnetic resonance venography, angiography, or autopsy in all patients in accordance with international guidelines.14

Controls were healthy individuals who participated in the Dutch Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study.15 The MEGA study is a case-control study performed in the Netherlands that included 4956 consecutive patients aged 18 to 70 years with a first deep vein thrombosis of the leg or pulmonary embolism from March 1, 1999, through September 31, 2004. Details of this study have been reported.15 Partners of patients and individuals identified by random digit dialing were asked to participate as controls. In total, 6297 controls (3297 partners and 3000 identified by random digit dialing) were included. These participants were between the ages of 18 and 70 years and had no history of venous thrombosis. We excluded women (cases and controls) who were pregnant or had given birth less than 12 weeks earlier.

The Medical Ethics Committee Academic Medical Center, Committee Medical Ethics Leiden University Medical Centre, and Cantonal Ethics Commission Bern approved the study. Written informed consent was obtained from all participants included in the MEGA study and the Berne cohort. For the patients with CVT included in the Amsterdam cohort, written informed consent was not required under Dutch law because only observational data were collected.

Data Collection and Definition of Obesity

Baseline characteristics, risk factors for thrombosis, imaging findings, and clinical outcome were recorded using a standardized case report form for cases. Each control completed a detailed questionnaire on acquired risk factors for thrombosis, which included self-reported current height and weight. In accordance with the definitions of the World Health Organization, BMI was categorized as follows: normal weight, BMI less than 25; overweight, BMI of 25 to 29.99; and obesity, BMI of 30 or greater.

Statistical Analysis

A multiple imputation procedure was used for missing data on height, weight, oral contraceptive use, smoking status, history of cancer, and ethnicity.16 In total, 5 data sets were imputed, and results were pooled according to Rubin’s rules. We applied multivariate logistic regression analysis to study the association between obesity and CVT. Individuals with a normal BMI (<25) were the reference category. In a separate analysis, we included BMI as a continuous variable in the model. Unadjusted and adjusted odds ratios (ORs) with 95% CIs were calculated. We adjusted for the following prespecified variables: sex, age (as a continuous variable), history of cancer, ethnicity, smoking status, and oral contraceptive use. On the basis of a previous report,4 we performed predefined subgroup analyses in which we studied the influence of sex and oral contraceptive use on the association between obesity and CVT. P < .05 was considered statistically significant. All data were analyzed with SPSS statistical software, version 20 (SPSS Inc).

Results

There were 192 cases and 6297 controls within the specified period. We excluded 6 cases and 163 controls because of pregnancy or recent delivery; therefore, the study population consisted of 186 cases and 6134 controls. The numbers of patients for whom data were missing were as follows: height, 547 (64 cases and 483 controls); weight, 539 (57 cases and 482 controls); oral contraceptive use, 32 (6 cases and 26 controls); history of cancer, 20 (1 case and 19 controls); smoking status, 487 (57 cases and 430 controls); and ethnicity, 423 (38 cases and 385 controls). In total, BMI could not be calculated without imputation in 69 cases because height or weight was not available. Eleven of these cases (15.9%) had obesity listed in their medical history.

Cases were younger (median age, 40 vs 48 years), more often female (133 [71.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] women), and more frequently had a history of cancer (17 [9.1%] vs 235 [3.8%]) compared with controls (Table 1). The most common clinical manifestations of patients with CVT are provided in Table 2.

Mean BMI was higher in cases than controls (26.7 vs 25.6, P = .01). After adjustment for confounding variables, the risk of CVT was increased in patients with obesity (BMI ≥30; adjusted OR, 2.63; 95% CI, 1.53-4.54) compared with patients with a normal BMI (Table 3). Overweight (BMI 25.0-29.99) was not associated with CVT (adjusted OR, 1.37; 95% CI, 0.80-2.36). When included as a continuous variable, BMI was also associated with an increased risk of CVT (adjusted OR per 1-unit increase in BMI, 1.09; 95% CI, 1.05-1.13; P < .001).

Stratification by sex revealed no statistically significant association between obesity and the risk of CVT in men (adjusted OR, 1.16; 95% CI, 0.25-5.30; Table 4). In women, overweight and obesity were associated with CVT (BMI 25-29.9: adjusted OR, 1.71; 95% CI, 1.01-2.91; BMI ≥30: adjusted OR, 3.50; 95% CI, 2.00-6.14).

We also stratified for oral contraceptive use (Table 5). Among women who did not use oral contraceptives, we found no association between obesity and CVT (BMI ≥30: adjusted OR, 1.29; 95% CI, 0.46-3.66). In contrast, in women who used oral contraceptives, obesity was strongly associated with the risk of CVT. Compared with women with a normal weight who did not use oral contraceptives, obese women taking oral contraceptives had a 29-fold increased risk of CVT (adjusted OR, 29.26; 95% CI, 13.47-63.60). The risk of CVT was also increased in overweight women who used oral contraceptives (BMI 25-29.99: adjusted OR, 11.87; 95% CI, 5.94-23.74).

Discussion

Our study indicates that obesity (BMI ≥30) is associated with an increased risk of CVT. This association appears to be fully attributable to a strongly increased risk in women who use oral contraceptives. Among these women, obesity was associated with an almost 30-fold increased risk of CVT compared with women of normal weight who did not use oral contraceptives. In men and women who do not use oral contraceptives, we found no association between CVT and obesity.

In VTE, the association with obesity is also stronger in women than men. In a large cohort study,5 a BMI in the highest quartile increased the risk of VTE 2.8-fold for women and 1.7-fold for men. Another study3 confirmed similar effect sizes. Only a few studies4,17,18 have examined the interaction between oral contraceptive use and obesity on the risk of VTE. Pomp et al4 found an OR of 24 among women with a BMI of 30 or greater who used oral contraceptives compared with nonusers of oral contraceptives who were of normal weight. In another study,17 the risk of VTE in oral contraceptive users with a BMI of 30 or greater was increased approximately 10-fold. A possible interaction between oral contraceptives and obesity has also been observed in ischemic stroke. In a case-control study by Kemmeren et al,18 the risk of ischemic stroke in women who used oral contraceptives was approximately doubled in those with obesity.

Among oral contraceptive users, the risk of CVT was higher in those with obesity (BMI ≥30) than in women who were overweight (BMI 25-29.99). This dose-response effect, in combination with the magnitude of the effect size and the evidence that obesity is also associated with VTE,2,4,19 favors a causal association among obesity, oral contraceptive use, and CVT.20 One mechanism by which obesity could increase the risk of thrombosis are changes in coagulation factor levels. Compared with women with a normal weight, obese women have higher plasma concentrations of prothrombotic factors, such as plasminogen activator inhibitor 1 and von Willebrand factor.21 Obesity is also associated with increased activated protein C resistance and higher concentrations of factor VIII, which are risk factors for thrombosis.22 Use of oral contraceptives also leads to increased activated protein C resistance,23 which might explain the synergistic effect of both risk factors that we observed.

It is important to determine whether the control group we used is representative of the healthy population. In our study, the prevalence of a BMI of 30 or greater was 12.6% and 13.8% among male and female controls, respectively. These percentages are similar to the findings of a study24 among healthy adults from the Netherlands that was performed in the same period as the MEGA study. The prevalence of a BMI above 25 among men and women is also comparable to the results of that study.

Of interest, obesity is also a risk factor for idiopathic intracranial hypertension (IIH). Patients with IIH most often present with headache, papilledema, and decreased visual acuity. Identical symptoms occur in intracranial hypertension owing to impaired venous return in patients with chronic CVT.25 Before the introduction of computed tomography and magnetic resonance venography, it was not uncommon for patients with CVT to be misdiagnosed as having IIH.26,27 Like CVT, IIH is far more common in women than in men, and the association between IIH and obesity is also stronger in women than men.2830 Given these resemblances, it is intriguing to speculate on a possible common pathogenesis by which obesity increases the risk of both conditions in women. It has been hypothesized that IIH is caused by decreased outflow from the cerebral venous system, possibly owing to stenosis of the transverse sinuses or insufficiency of the valves in the jugular veins.31,32 Studies31,33 have suggested that obesity enhances this mechanism by transmittance of increased intra-abdominal pressure to the cerebral venous system. On the other hand, there are also data indicating that the sinus stenosis seen in IIH is secondary to the increased intracranial pressure and is reversible after removal of cerebrospinal fluid.34 The effect of stenting of the cerebral sinuses has been examined in patients with IIH but only in small and uncontrolled series, and the data are inconclusive.35,36 Prospective studies37,38 evaluating the efficacy of cerebral venous sinus stenting in IIH are currently ongoing.

Our study has several limitations. First, we could include only a relatively small number of patients with CVT, especially men and women without oral contraceptive use. We cannot exclude that the absent association between obesity and CVT in these groups is the result of this limited sample size. Second, we were unable to examine whether genetic thrombophilia influences the association between obesity and CVT because screening for thrombophilia was not performed in most cases. Thrombophilia should be the focus of a future study given that there is a synergistic effect between oral contraceptives and thrombophilia on the risk of CVT9,39 and between obesity and thrombophilia on the risk of VTE.4 Third, data on the key variables of height and weight were missing in a substantial proportion of cases because these measurements were not recorded in all patients. This lack of data on height and weight could have underpowered the study and biased the results if the reason the data were missing was not random. To minimize this potential bias, we used a multiple imputation procedure.16,40 The fact that 15.9% of cases in which no BMI could be calculated had obesity listed in their medical history also suggests that obesity was not infrequent among cases with missing BMI. Fourth, instead of measuring height and weight, we used self-reported data to calculate BMI, which could be less accurate, although a previous study6 found an excellent correlation between self-reported and measured BMI. Moreover, because measurements were self-reported for cases and controls, any inaccuracy would be expected to affect both groups, which would decrease the risk of bias. Fifth, there was a time difference in recruitment between cases and controls. The controls were recruited from March 1, 1999, through September 31, 2004, whereas the cases were recruited from July 1, 2006 (Amsterdam), and October 1, 2009 (Berne), through December 31, 2014. A change in prevalence of obesity in that period could theoretically have biased the results. However, the time difference seems to be too small to explain the results and would also not explain why we only observed an association in women who used oral contraceptives. Finally, we cannot exclude the possibility that residual confounding influenced the results. Some variables, such as obstructive sleep apnea syndrome, were not available for controls. Obstructive sleep apnea syndrome is a risk factor for obesity and VTE, although, to our knowledge, an association with CVT has never been reported.41,42

The increased risk of VTE and CVT associated with oral contraceptives in the presence of obesity might make physicians reluctant to prescribe oral contraceptives to obese women. However, although the relative risks are increased substantially, the absolute risks of CVT are still small.43 Moreover, withholding oral contraceptives may lead to an increase in unintended pregnancies and thus the number of pregnancy-related thrombosis cases.44 Nevertheless, obese women should be informed about the increased risk of thrombosis if they use oral contraceptives, especially if other risk factors are present. Alternative methods of contraception that are not associated with thrombosis, such as an intrauterine device, might be offered to these women.

Conclusions

To our knowledge, this is the first case-control study that examined the association between obesity and CVT. Our results suggest that obesity is associated with a substantially increased risk of CVT in women who use oral contraceptives. This increased risk should be taken into consideration when prescribing oral contraceptives to obese women.

Back to top
Article Information

Accepted for Publication: December 21, 2015.

Corresponding Author: Jonathan M. Coutinho, MD, PhD, Department of Neurology, Academic Medical Centre, Meibergdreef 9, 1105 AZ, PO Box 22660, Amsterdam, the Netherlands (j.coutinho@amc.nl).

Published Online: March 14, 2016. doi:10.1001/jamaneurol.2016.0001.

Author Contributions: Drs Arnold and Zuurbier contributed equally to this work. Dr Coutinho had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Zuurbier, Arnold, Middeldorp, Stam, Cannegieter, Coutinho.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Zuurbier, Coutinho.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Zuurbier, Silvis, Nemeth, Cannegieter, Coutinho.

Obtained funding: Arnold.

Administrative, technical, or material support: Broeg-Morvay, Silvis, Heldner, Meisterernst, Meulendijks, Cannegieter.

Study supervision: Arnold, Middeldorp, Stam, Coutinho.

Conflict of Interest Disclosures: Dr Arnold reported received honoraria for lectures and advisory boards from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien. No other disclosures were reported.

Funding/Support: This study is supported by grant 021.001.045 from The Netherlands Organisation for Scientific Research, grant 2012-2 from the Dutch Thrombosis Society, and the Remmert Adriaan Laan Foundation (Dr Coutinho) and the Swiss Heart Foundation (Dr Arnold).

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

References
1.
Brækkan  SK, Hald  EM, Mathiesen  EB,  et al.  Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study.  Arterioscler Thromb Vasc Biol. 2012;32(2):487-491.PubMedArticle
2.
Tsai  AW, Cushman  M, Rosamond  WD, Heckbert  SR, Polak  JF, Folsom  AR.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.  Arch Intern Med. 2002;162(10):1182-1189.PubMedArticle
3.
Holst  AG, Jensen  G, Prescott  E.  Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study.  Circulation. 2010;121(17):1896-1903.PubMedArticle
4.
Pomp  ER, le Cessie  S, Rosendaal  FR, Doggen  CJ.  Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.  Br J Haematol. 2007;139(2):289-296.PubMedArticle
5.
Severinsen  MT, Kristensen  SR, Johnsen  SP, Dethlefsen  C, Tjønneland  A, Overvad  K.  Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.  Circulation. 2009;120(19):1850-1857.PubMedArticle
6.
Parkin  L, Sweetland  S, Balkwill  A, Green  J, Reeves  G, Beral  V; Million Women Study Collaborators.  Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study.  Circulation. 2012;125(15):1897-1904.PubMedArticle
7.
Zuurbier  SM, van den Berg  R, Troost  D, Majoie  CB, Stam  J, Coutinho  JM.  Hydrocephalus in cerebral venous thrombosis.  J Neurol. 2015;262(4):931-937.PubMedArticle
8.
Stam  J.  Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;352(17):1791-1798.PubMedArticle
9.
de Bruijn  SF, Stam  J, Koopman  MM, Vandenbroucke  JP; The Cerebral Venous Sinus Thrombosis Study Group.  Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions.  BMJ. 1998;316(7131):589-592.PubMedArticle
10.
Koopman  K, Uyttenboogaart  M, Vroomen  PC, van der Meer  J, De Keyser  J, Luijckx  GJ.  Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years.  Thromb Haemost. 2009;102(4):620-622.PubMed
11.
Zuurbier  SM, Lauw  MN, Coutinho  JM,  et al.  Clinical course of cerebral venous thrombosis in adult acute lymphoblastic leukemia.  J Stroke Cerebrovasc Dis. 2015;24(7):1679-1684.PubMedArticle
12.
Pearson  V, Ruzas  C, Krebs  NF, Goldenberg  NA, Manco-Johnson  MJ, Bernard  TJ.  Overweight and obesity are increased in childhood-onset cerebrovascular disease.  J Child Neurol. 2013;28(4):517-519.PubMedArticle
13.
deVeber  G, Andrew  M, Adams  C,  et al; Canadian Pediatric Ischemic Stroke Study Group.  Cerebral sinovenous thrombosis in children.  N Engl J Med. 2001;345(6):417-423.PubMedArticle
14.
Saposnik  G, Barinagarrementeria  F, Brown  RD  Jr,  et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention.  Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.  Stroke. 2011;42(4):1158-1192.PubMedArticle
15.
Blom  JW, Doggen  CJ, Osanto  S, Rosendaal  FR.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;293(6):715-722.PubMedArticle
16.
Donders  AR, van der Heijden  GJ, Stijnen  T, Moons  KG.  Review: a gentle introduction to imputation of missing values.  J Clin Epidemiol. 2006;59(10):1087-1091.PubMedArticle
17.
Abdollahi  M, Cushman  M, Rosendaal  FR.  Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;89(3):493-498.PubMed
18.
Kemmeren  JM, Tanis  BC, van den Bosch  MA,  et al.  Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.  Stroke. 2002;33(5):1202-1208.PubMedArticle
19.
Goldhaber  SZ, Grodstein  F, Stampfer  MJ,  et al.  A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;277(8):642-645.PubMedArticle
20.
Bonita  R, Beaglehole  R, Kjellstrom  T.  Environmental and Occupational Epidemiology: Basic Epidemiology. 2nd ed. Geneva, Switzerland: World Health Organization; 2006:93-95.
21.
De Pergola  G, De Mitrio  V, Giorgino  F,  et al.  Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution.  Int J Obes Relat Metab Disord. 1997;21(7):527-535.PubMedArticle
22.
Christiansen  SC, Lijfering  WM, Naess  IA,  et al.  The relationship between body mass index, activated protein C resistance and risk of venous thrombosis.  J Thromb Haemost. 2012;10(9):1761-1767.PubMedArticle
23.
Rosing  J, Middeldorp  S, Curvers  J,  et al.  Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.  Lancet. 1999;354(9195):2036-2040.PubMedArticle
24.
Schokker  DF, Visscher  TL, Nooyens  AC, van Baak  MA, Seidell  JC.  Prevalence of overweight and obesity in the Netherlands.  Obes Rev. 2007;8(2):101-108.PubMedArticle
25.
Wall  M, Kupersmith  MJ, Kieburtz  KD,  et al; NORDIC Idiopathic Intracranial Hypertension Study Group.  The Idiopathic Intracranial Hypertension Treatment Trial: clinical profile at baseline.  JAMA Neurol. 2014;71(6):693-701.PubMedArticle
26.
Biousse  V, Ameri  A, Bousser  MG.  Isolated intracranial hypertension as the only sign of cerebral venous thrombosis.  Neurology. 1999;53(7):1537-1542.PubMedArticle
27.
Leker  RR, Steiner  I.  Features of dural sinus thrombosis simulating pseudotumor cerebri.  Eur J Neurol. 1999;6(5):601-604.PubMedArticle
28.
Kesler  A, Goldhammer  Y, Gadoth  N.  Do men with pseudomotor cerebri share the same characteristics as women? a retrospective review of 141 cases.  J Neuroophthalmol. 2001;21(1):15-17.PubMedArticle
29.
Ferro  JM, Canhão  P, Stam  J, Bousser  MG, Barinagarrementeria  F; ISCVT Investigators.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).  Stroke. 2004;35(3):664-670.PubMedArticle
30.
Balcer  LJ, Liu  GT, Forman  S,  et al.  Idiopathic intracranial hypertension: relation of age and obesity in children.  Neurology. 1999;52(4):870-872.PubMedArticle
31.
Nedelmann  M, Kaps  M, Mueller-Forell  W.  Venous obstruction and jugular valve insufficiency in idiopathic intracranial hypertension.  J Neurol. 2009;256(6):964-969.PubMedArticle
32.
Wakerley  BR, Tan  MH, Ting  EY.  Idiopathic intracranial hypertension.  Cephalalgia. 2015;35(3):248-261.PubMedArticle
33.
Sugerman  HJ, DeMaria  EJ, Felton  WL  III, Nakatsuka  M, Sismanis  A.  Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri.  Neurology. 1997;49(2):507-511.PubMedArticle
34.
Rohr  A, Dörner  L, Stingele  R, Buhl  R, Alfke  K, Jansen  O.  Reversibility of venous sinus obstruction in idiopathic intracranial hypertension.  AJNR Am J Neuroradiol. 2007;28(4):656-659.PubMed
35.
Puffer  RC, Mustafa  W, Lanzino  G.  Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature.  J Neurointerv Surg. 2013;5(5):483-486.PubMedArticle
36.
Piper  RJ, Kalyvas  AV, Young  AM, Hughes  MA, Jamjoom  AA, Fouyas  IP.  Interventions for idiopathic intracranial hypertension.  Cochrane Database Syst Rev. 2015;8:CD003434.PubMed
37.
ClinicalTrials.gov. Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy (VSSIIH). NCT01407809. https://clinicaltrials.gov/ct2/show/NCT01407809. Accessed December 1, 2015.
38.
ClinicalTrials.gov. Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension. NCT02143258. https://clinicaltrials.gov/ct2/show/NCT02143258. Accessed December 1, 2015.
39.
Martinelli  I, Sacchi  E, Landi  G, Taioli  E, Duca  F, Mannucci  PM.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.  N Engl J Med. 1998;338(25):1793-1797.PubMedArticle
40.
Moons  KG, Donders  RA, Stijnen  T, Harrell  FE  Jr.  Using the outcome for imputation of missing predictor values was preferred.  J Clin Epidemiol. 2006;59(10):1092-1101.PubMedArticle
41.
Chou  KT, Huang  CC, Chen  YM,  et al.  Sleep apnea and risk of deep vein thrombosis: a non-randomized, pair-matched cohort study.  Am J Med. 2012;125(4):374-380.PubMedArticle
42.
Jordan  AS, McSharry  DG, Malhotra  A.  Adult obstructive sleep apnoea.  Lancet. 2014;383(9918):736-747.PubMedArticle
43.
Middeldorp  S.  Thrombosis in women: what are the knowledge gaps in 2013?  J Thromb Haemost. 2013;11(suppl 1):180-191.PubMedArticle
44.
van Vlijmen  EF, Veeger  NJ, Middeldorp  S,  et al.  Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.  Blood. 2011;118(8):2055-2061.PubMedArticle
×